Share

January 2022; 9 (1) ArticleOpen Access

Recovery From COVID-19 in Multiple Sclerosis

A Prospective and Longitudinal Cohort Study of the United Kingdom Multiple Sclerosis Register

Afagh Garjani, Rodden M. Middleton, Richard Nicholas, Nikos Evangelou
First published November 30, 2021, DOI: https://doi.org/10.1212/NXI.0000000000001118
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
2216

Share

Article Information

vol. 9 no. 1 e1118
DOI: 
https://doi.org/10.1212/NXI.0000000000001118
PubMed: 
34848503
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received July 2, 2021
  • Accepted in final form October 7, 2021
  • First Published November 30, 2021.
Copyright & Usage: 
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Afagh Garjani, MD,
    2. Rodden M. Middleton, MBA,
    3. Richard Nicholas, FRCP and
    4. Nikos Evangelou, FRCP
  1. Afagh Garjani, MD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Novartis, Travel support, (2) Merck, Travel support, (3) Multiple Sclerosis Academy, Travel support, (4) Speaker honorarium, Multiple Sclerosis Academy

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) United Kingdom Multiple Sclerosis Society

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Rodden M. Middleton, MBA,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. MS Society UK MS Register Award 112

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Richard Nicholas, FRCP and
    4. Scientific Advisory Boards:

    1. (1) Roche (2) Novartis (3) Biogen

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Biogen

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. (1) Standing Member National Institute of health and care excellence HTA committee C

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) UK MS Society (2) Berkeley Foundation (3) MSTC

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Nikos Evangelou, FRCP
    5. Scientific Advisory Boards:

    1. Compensation received for serving at advisory boards for Novartis, Biogen,Genzyme, Merck,Roche

    Gifts:

    1. Travel assistance to attend neurology conferences received by Novartis,Biogen, Teva

    Funding for travel or speaker honoraria:

    1. Speaker Honorarium received from Roche, Biogen and Novartis

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. PCORI , co PI, Determining the Effectiveness of Early Intensive versus Escalation Approaches for the Treatment of Relapsing-Remitting Multiple Sclerosis (DELIVER-MS)

    Research Support, Academic Entities:

    1. Medical Research council: Explaining cognitive impairment in multiple sclerosis through integrated structural and functional networks, CiC MRC, July 2017-18, 97,316

    Research Support, Foundations and Societies:

    1. Intervention to support individuals around the point of Multiple Sclerosis diagnosis MS society, January 2017-2020

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Mental Health and Clinical Neurosciences Academic Unit, School of Medicine (A.G., N.E.), University of Nottingham; Clinical Neurology (A.G., N.E.), Nottingham University Hospitals NHS Trust; Population Data Science (R.M.M.), Swansea University Medical School; and Department of Cellular and Molecular Neuroscience (R.N.), Imperial College London, United Kingdom.
  1. Correspondence
    Dr. Evangelou nikos.evangelou{at}nottingham.ac.uk

Article usage

Article usage: November 2021 to November 2023

AbstractFullPdfSource
Nov 202101174Highwire
Dec 202161484282Highwire
Jan 2022183145625Highwire
Feb 2022172805152Highwire
Mar 202242177144Highwire
Apr 20226215156Highwire
May 202252387120Highwire
Jun 20227245376Highwire
Jul 202273295107Highwire
Aug 202220237551Highwire
Sep 202221261774Highwire
Oct 202221193368Highwire
Nov 202217134653Highwire
Dec 202215114645Highwire
Jan 202313106440Highwire
Feb 2023893542Highwire
Mar 2023979135Highwire
Apr 20231250347Highwire
May 20231060039Highwire
Jun 20231144335Highwire
Jul 20231136736Highwire
Aug 2023839638Highwire
Sep 20231424319Highwire
Oct 2023102079Highwire
Nov 20231221019Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. [email protected]
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me